dc.contributor.author | Madsen, Anders | |
dc.contributor.author | Brokstad, Rebecca Jane Cox | |
dc.date.accessioned | 2021-07-07T07:39:42Z | |
dc.date.available | 2021-07-07T07:39:42Z | |
dc.date.created | 2020-07-29T13:26:32Z | |
dc.date.issued | 2020-07-06 | |
dc.Published | Vaccines. 2020, 8 (3), 1-12. | |
dc.identifier.issn | 2076-393X | |
dc.identifier.uri | https://hdl.handle.net/11250/2763650 | |
dc.description.abstract | Current influenza vaccines offer suboptimal protection and depend on annual reformulation and yearly administration. Vaccine technology has rapidly advanced during the last decade, facilitating development of next-generation influenza vaccines that can target a broader range of influenza viruses. The development and licensure of a universal influenza vaccine could provide a game changing option for the control of influenza by protecting against all influenza A and B viruses. Here we review important findings and considerations regarding the development of universal influenza vaccines and what we can learn from this moving forward with a SARS-CoV-2 vaccine design. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Prospects and challenges in the development of universal influenza vaccines | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright the authors | en_US |
dc.source.articlenumber | 361 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/vaccines8030361 | |
dc.identifier.cristin | 1820905 | |
dc.source.journal | Vaccines | en_US |
dc.source.40 | 8 | |
dc.source.14 | 3 | |
dc.relation.project | Norges forskningsråd: 271160 | en_US |
dc.relation.project | Norges forskningsråd: 284930 | en_US |
dc.relation.project | Norges forskningsråd: 811752 | en_US |
dc.relation.project | Norges forskningsråd: 815818 | en_US |
dc.identifier.citation | Vaccines. 2020, 8, 361. | en_US |
dc.source.volume | 8 | en_US |